Dr Reddy's To Market Amgen Therapies In India
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories is to market and distribute three Amgen therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) on the Indian market.
You may also be interested in...
Amgen-Dr Reddy's Build On India Alliance
Amgen is building on its alliance with Dr. Reddy’s Laboratories in India, shifting out certain products previously sold by GlaxoSmithKline in the country to the Hyderabad-based firm.
Amgen's Repatha India Trial Waiver Plan Trips Up
Amgen's PCSK9 inhibitor Repatha, already constrained by payor pushbacks on prices in the West and awaiting outcomes data, now appears to be facing a challenge in India. A key Indian expert panel has turned down Amgen's request for a trial waiver for evolocumab, a move that could hold up launch plans with partner Dr Reddy's.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.